---
title: "Trans Tech: Holding subsidiary wins a project worth 45.5565 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/230800473.md"
description: "Trans Tech's subsidiary Nanjing Gandong Technology Co., Ltd. won the bid for the project of Jiangsu Sutong Bridge Co., Ltd., with an amount of 45.5565 million yuan. The project involves the construction of smart control, smart stations, smart services, etc., and is scheduled to be completed within 9 months after the contract takes effect"
datetime: "2025-03-06T09:29:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/230800473.md)
  - [en](https://longbridge.com/en/news/230800473.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/230800473.md)
generator: "portal-rs"
---

# Trans Tech: Holding subsidiary wins a project worth 45.5565 million yuan

Trans Tech announced that its controlling subsidiary, Nanjing GanDong Technology Co., Ltd., recently received a bid notification from Jiangsu Sutong Bridge Co., Ltd., confirming GanDong Technology as the winning bidder for the "2025 Sutong Bridge Tongxi Expressway Haimen to Tongzhou Section Intelligent Upgrade Project." The total bid amount is 45.5565 million yuan. The project includes the construction of intelligent control applications, empowerment applications for intelligent stations, intelligent services, intelligent maintenance and operation construction, smart decision-making application construction, and the establishment of a digital foundation for the Nantong Ring City Intelligent Expressway. The construction period is to be completed within 9 months after the contract takes effect

### Related Stocks

- [301339.CN](https://longbridge.com/en/quote/301339.CN.md)

## Related News & Research

- [Fibocom wins China antitrust clearance for 37.16% Hangsheng Electronics stake purchase](https://longbridge.com/en/news/296214384.md)
- [Cell C publishes FY2026 annual report](https://longbridge.com/en/news/296585950.md)
- [Innventure directors force management, board to forfeit Accelsius earnout shares tied to DarkNX order](https://longbridge.com/en/news/296352522.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)
- [Tvardi Therapeutics: TTI-109 targets STAT3 to address unmet needs in UC with selective immune modulation and safety](https://longbridge.com/en/news/296374826.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**